--- title: "LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of \"Moderate Buy\" from Analysts" description: "LivaNova PLC (NASDAQ:LIVN) has received a consensus rating of \"Moderate Buy\" from eight analysts. The average 1-year price target is $61.17, with two analysts recommending hold, five buy, and one stro" type: "news" locale: "en" url: "https://longbridge.com/en/news/231641790.md" published_at: "2025-03-13T06:20:19.000Z" --- # LivaNova PLC (NASDAQ:LIVN) Receives Average Rating of "Moderate Buy" from Analysts > LivaNova PLC (NASDAQ:LIVN) has received a consensus rating of "Moderate Buy" from eight analysts. The average 1-year price target is $61.17, with two analysts recommending hold, five buy, and one strong buy. Recent price target adjustments include Mizuho lowering it from $70 to $60, and Barclays from $58 to $56. Institutional investors own 97.64% of the stock, which opened at $39.07, with a 52-week range of $36.85 to $64.47. Shares of LivaNova PLC (NASDAQ:LIVN - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $61.17. A number of brokerages recently weighed in on LIVN. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research report on Wednesday, February 26th. Wolfe Research cut shares of LivaNova from an "outperform" rating to a "peer perform" rating in a research report on Wednesday, February 26th. Barclays decreased their price target on shares of LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research report on Friday, March 7th. The Goldman Sachs Group decreased their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, Stifel Nicolaus decreased their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. **Check Out Our Latest Analysis on LivaNova** ## Hedge Funds Weigh In On LivaNova A number of large investors have recently bought and sold shares of LIVN. Russell Investments Group Ltd. lifted its holdings in LivaNova by 17.1% in the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company's stock worth $70,000 after acquiring an additional 219 shares during the last quarter. Sterling Capital Management LLC lifted its holdings in LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company's stock worth $75,000 after acquiring an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division lifted its holdings in LivaNova by 21.2% in the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company's stock worth $191,000 after acquiring an additional 720 shares during the last quarter. Vestcor Inc acquired a new stake in shares of LivaNova in the fourth quarter valued at approximately $204,000. Finally, Optimize Financial Inc acquired a new stake in shares of LivaNova in the fourth quarter valued at approximately $208,000. Institutional investors own 97.64% of the company's stock. ## LivaNova Stock Up 0.0 % Shares of NASDAQ LIVN opened at $39.07 on Thursday. LivaNova has a 52-week low of $36.85 and a 52-week high of $64.47. The firm has a fifty day moving average of $46.32 and a 200-day moving average of $49.18. The stock has a market capitalization of $2.12 billion, a PE ratio of 93.02 and a beta of 1.10. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. ## LivaNova Company Profile (Get Free Report LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. ## Featured Stories - Five stocks we like better than LivaNova - Retail Stocks Investing, Explained - Ramaco Resources Pins Hopes on Coal's Untapped Potential - How to Use Stock Screeners to Find Stocks - NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy - 3 Best Fintech Stocks for a Portfolio Boost - Why Energy Transfer Belongs on Your Watchlist *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in LivaNova Right Now? Before you consider LivaNova, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list. While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [LIVN.US - Livanova](https://longbridge.com/en/quote/LIVN.US.md) - [MFG.US - Mizuho Financial](https://longbridge.com/en/quote/MFG.US.md) - [BCS.US - Barclays](https://longbridge.com/en/quote/BCS.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | 08:02 ET Orrum 宣佈與 Livanova 達成戰略合作伙伴關係，結合智能數據與創新的灌注技術 | Orrum Clinical Analytics 宣佈與 LivaNova USA Inc. 建立戰略合作伙伴關係，將 LivaNova 的 Essenz™ 灌注系統與 Orrum 的 CŌRE Insights™ 分析平台整合。此次合作旨 | [Link](https://longbridge.com/en/news/276444458.md) | | LivaNova 的首席法務官 Michael Hutchinson 宣佈辭職 | LivaNova plc 宣佈邁克爾·哈欽森（Michael Hutchinson）辭去高級副總裁、首席法律官和公司秘書職務，辭職日期為 2026 年 1 月 26 日。公司將尋求外部獵頭公司的協助，尋找新的首席法律官 | [Link](https://longbridge.com/en/news/272560833.md) | | XVIVO Perfusion 提名了經驗豐富的醫療行業領導者，以增強董事會的實力 | XVIVO Perfusion AB 宣佈在 2026 年 4 月 27 日的年度股東大會之前，重新選舉四名董事，並新增兩名董事，Emil Billbäck 和 Anne-Karen Hunt。此舉旨在增強公司治理和戰略能力，以支持其全球移 | [Link](https://longbridge.com/en/news/276447216.md) | | XVIVO Perfusion AB（公開）提名委員會提議 Emil Billbäck 和 Anne-Karen Hunt 擔任董事會新成員 | XVIVO Perfusion AB 的提名委員會提議 Emil Billbäck 和 Anne-Karen Hunt 在 2026 年 4 月 27 日的年度股東大會上選舉為董事會成員。Billbäck 在醫療保健領域擁有超過 30 年的 | [Link](https://longbridge.com/en/news/276446321.md) | | 來源更正：提名委員會關於新董事會成員的提案 | XVIVO Perfusion AB 發佈了關於其提名委員會在 2026 年 4 月 27 日年度股東大會之前提名新董事的提案的更正。更新後的提案包括重新選舉 Göran Dellgren，以及 Gösta Johannesson、Cami | [Link](https://longbridge.com/en/news/276449687.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.